Turning Point

Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines

05/12/2022

Strategic Expansion of Turning Point Precision Oncology Portfolio TPX-4589 (LM-302) Currently in Two Ongoing Phase 1 Studies Agreement Includes Potential Broader Scope to Collaborate on up to Three Additional ADC Programs Excerpt from the Press Release: SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company…

Read More

Recent Updates

Categories

Archives

RSS Feed